Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination therapy containing three active ingredients: - **Alendronate sodium** is a bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby reducing bone turnover and increasing bone mineral density. It is primarily used to treat and prevent osteoporosis by slowing the breakdown of bone and allowing for increased bone formation. - **Vitamin D3 (cholecalciferol)** facilitates intestinal absorption of calcium and phosphorus, which are essential for maintaining healthy bones. Adequate vitamin D levels are necessary for effective calcium absorption. - **Calcium carbonate** provides supplemental elemental calcium, an essential mineral required to maintain the structural integrity of bones. The combination is indicated for the treatment of osteoporosis in postmenopausal women and men at risk of or diagnosed with osteoporosis, providing both antiresorptive therapy (alendronate) and supplementation with vitamin D3 and calcium to optimize bone health[4][1][2]. The product aims to address multiple aspects of osteoporosis management by combining agents that work synergistically on different pathways involved in bone metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + vitamin D3 + alendronate sodium.